Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | SHBG | P04278 | 2/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.62 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10893814 | 1.00 | ALDH1A1 (0.62) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL9360183 | 0.94 | CYP3A4 (0.62) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL6684640 | 0.93 | CYP3A4 (0.61) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL28718285 | 0.91 | CYP3A4 (0.59) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL28255051 | 0.91 | CYP3A4 (0.59) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL138289 | 0.91 | ALDH1A1 (0.67) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL27681847 | 0.90 | CYP3A4 (0.58) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL2042111 | 0.90 | CYP3A4 (0.58) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL11023737 | 0.90 | CYP3A4 (0.60) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL8015127 | 0.90 | LMNA (0.60) | ALDH1A1CYP3A4SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260133508-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2026-05-14 | — | — | US | claimed |
| EP-4741932-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM Business Innovation Corp. (JP) | 2026-05-13 | — | — | EP | claimed |
| CN-122018258-A | Electrophotographic photoreceptor, process cartridge, and image forming apparatus | 富士胶片商业创新有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250319100-A1 | ANTI-TUMOR COMBINED PREPARATION COMPRISING HYDROXYPROGESTERONE CAPROATE AND USE THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. (CN) | 2025-10-16 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| US-12316378-B2 | Optical high-power amplifier circuit with switchable polarized output state | THE BOEING COMPANY (US) | 2025-05-27 | — | — | US | claimed |
| CN-119173283-A | Radiopharmaceutical complexes targeting prostate specific membrane antigen and combinations thereof | 拜耳股份有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-118858479-A | Kit for simultaneously detecting 90 steroid hormones and metabolites thereof in urine sample, detection method and sample pretreatment method | 中国疾病预防控制中心环境与健康相关产品安全所 | 2024-10-29 | — | — | CN | claimed |
| US-20240243810-A1 | OPTICAL HIGH-POWER AMPLIFIER CIRCUIT WITH SWITCHABLE POLARIZED OUTPUT STATE | THE BOEING COMPANY (US) | 2024-07-18 | — | — | US | claimed |
| EP-4309658-A1 | ANTI-TUMOR COMBINED PREPARATION COMPRISING HYDROXYPROGESTERONE CAPROATE AND USE THEREOF | Shenzhen Evergreen Therapeutics Co., Ltd. (CN) | 2024-01-24 | — | — | EP | claimed |
| US-5906830-A | POLYMER, DRUG MIXTURE | CYGNUS, INC. (US) | 1999-05-25 | — | — | US | claimed |
| US-5902603-A | INCLUDING A PERMEABILITY ENHANCER ABSORBED THEREIN; HIGHER LOADS; HIGH CAPACITY AND FLUX; CROSSLINKED POLYURETHANE REACTED WITH WATER; ADMINISTERING STEROIDS AND OLANZAPINE | CYGNUS, INC. (US) | 1999-05-11 | — | — | US | claimed |
| US-5891462-A | GEL MIXTURE CONTAINING PERMEABILITY ENHANCER | PERMATEC N.V. (NL) | 1999-04-06 | — | — | US | claimed |
| US-5788983-A | LEVONORGESTREL, 17-BETA ESTRADIOL, NORETHINDIONE, ETHYL ESTRADIOL, MEDROXY PROGESTERONE ACETATE, TESTOSTERONE | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-08-04 | — | — | US | claimed |
| WO-1997043989-A1 | COMPOSITIONS, METHODS AND DEVICES FOR THE TRANSDERMAL DELIVERY OF DRUGS | DIVERSIFIED PHARMACEUTICALS, INC. (US) | 1997-11-27 | — | — | WO | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| US-5164190-A | Hydrophobic drugs, steroids | THERATECH, INC. (US) | 1992-11-17 | — | — | US | claimed |
| CN-1041528-A | HORMONE PREPARATION AND METHOD | JENCAP RESEARCH LTD (CA) | 1990-04-25 | — | — | CN | claimed |
| US-4588529-A | Mercury removal process | THE UPJOHN COMPANY (US) | 1986-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260133508-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | SLC9A3, SLC9A1, HSPA4L | ALDH1A1 847/4885CYP3A4 4518/4885SMN1; SMN2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.